Regarding intrinsic TKI-resistance, though, relatively small cohorts of gefitinib- or erlotinib-treated NSCLC-patients comparable to ours have shown only a marginal negative impact of coexisting TP53-mutations on the OR to TKIs [26, 27]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.